{"created":"2023-06-20T16:49:52.409512+00:00","id":22187,"links":{},"metadata":{"_buckets":{"deposit":"1eabacd0-0235-4d64-9eab-c06337794ec2"},"_deposit":{"created_by":3,"id":"22187","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"22187"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00022187","sets":["14:2667:4710"]},"author_link":["43341"],"item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2021","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"5","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2020)"}]}]},"item_8_description_25":{"attribute_name":"リンクURL","attribute_value_mlt":[{"subitem_description":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19K16812/ | https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19K16812/","subitem_description_type":"Other"}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文）：進行再発非小細胞肺癌初回治療例を対象とした多施設共同研究を行った。PD-1阻害薬単独療法を行った106例を主対象とし、殺細胞薬のみで治療した105例、PD-1阻害薬＋殺細胞薬で治療した49例を対照群として集積し、治療効果と腫瘍量の関連性を検討した。殺細胞薬群では、腫瘍量と治療効果の関連性は認められなかったが、PD-1阻害薬単独治療群でその関連性が強く認められた。また、51例の腫瘍組織検体で遺伝子発現解析を行うと、腫瘍量が多い群は少ない群と比較して免疫抑制性シグナルが亢進していた。以上より、腫瘍量が多い場合には、特定の免疫状態によってPD-1阻害薬単独治療への耐性を示すことが示唆された。研究成果の概要（英文）：In this multi-institutional study, patients with treatment-naive metastatic non-small cell lung cancer (NSCLC) who received anti-PD-1 monotherapy (ICI-cohort, N=106), platinum-doublet therapy (Chemo-cohort, N=105), or anti-PD-1 with platinum-doublet therapy (ICI+Chemo-cohort, N=49) as their first-line treatment regimens were included to evaluate the association of tumor burden (TB) with treatment efficacy. This analysis showed significant association of high tumor burden with poor treatment efficacy only in ICI-cohort. Gene expression analysis of pretreatment tumor tissue from approximately 50 patients revealed that high tumor burden was associated with immunosuppressive phenotypes. Thus, this study suggested that high TB was associated with resistance to anti-PD-1 therapy in treatment-naive advanced NSCLC, possibly due to certain immunosuppressive phenotypes.","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：若手研究;  研究期間：2019～2020;   課題番号：19K16812;   研究分野：臨床腫瘍学;   科研費の分科・細目：","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"HARATANI, KOJI"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学大学病院; 助教"}]},"item_8_text_9":{"attribute_name":"著者所属(翻訳)","attribute_value_mlt":[{"subitem_text_value":"Kindai University"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_be7fb7dd8ff6fe43","subitem_version_type":"NA"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"原谷, 浩司"},{"creatorName":"ハラタニ, コウジ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2021-11-25"}],"displaytype":"detail","filename":"19K16812seika.pdf","filesize":[{"value":"1.0 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"19K16812seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/22187/files/19K16812seika.pdf"},"version_id":"e09243b0-2846-43d0-9e63-1a88f38fd265"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"非小細胞肺癌","subitem_subject_scheme":"Other"},{"subitem_subject":"免疫治療","subitem_subject_scheme":"Other"},{"subitem_subject":"腫瘍免疫","subitem_subject_scheme":"Other"},{"subitem_subject":"チェックポイント阻害薬","subitem_subject_scheme":"Other"},{"subitem_subject":"PD-1","subitem_subject_scheme":"Other"},{"subitem_subject":"耐性","subitem_subject_scheme":"Other"},{"subitem_subject":"腫瘍量","subitem_subject_scheme":"Other"},{"subitem_subject":"遺伝子発現","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"未治療進行非小細胞肺癌における治療前腫瘍量とPD-1阻害薬治療効果の関連性","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"未治療進行非小細胞肺癌における治療前腫瘍量とPD-1阻害薬治療効果の関連性"},{"subitem_title":"The association of tumor burden and anti-PD-1 inhibitor therapy efficacy in patients with untreated advanced non-small cell lung cancer.","subitem_title_language":"en"}]},"item_type_id":"8","owner":"3","path":["4710"],"pubdate":{"attribute_name":"公開日","attribute_value":"2021-11-25"},"publish_date":"2021-11-25","publish_status":"0","recid":"22187","relation_version_is_last":true,"title":["未治療進行非小細胞肺癌における治療前腫瘍量とPD-1阻害薬治療効果の関連性"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-06-20T19:46:06.697317+00:00"}